In this issue:
Sacituzumab govitecan in hormone receptor+, HER2– metastatic breast cancer
20-year follow-up of docetaxel-carboplatin-trastuzumab for metastatic HER2+ breast cancer
Differences between HER2-ultralow,-low and -null breast cancer
Influence of family history on penetrance of hereditary cancers
First-line pyrotinib + trastuzumab-docetaxel for HER2+ metastatic breast cancer
Associations of DCIS with post-treatment risk of breast cancer
Ovarian suppression + tamoxifen for premenopausal hormone receptor+breast cancer postchemotherapy
Neoadjuvant vs. adjuvant chemotherapy in node-negative T1 TNBC
Adjuvant chemo-endocrine therapy for pT1-2N0 early breast cancer, recurrence score ≥26, age >50
Acupuncture for pain in breast cancer survivors
Please login below to download this issue (PDF)